Morning all ..13 Jun 2022 10:46
Well done team scancell on getting its novel platform technology Moditope into the clinic ! A lot of hurdles successfully negotiated to get to this point!
For anyone new to scancell the ‘about scancell’ piece at the end of the RNS is always a great summary.
“ About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company’s unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).”
Lots going on ..
Granted it’s taken longer that I thought to get to this point but now it gets exciting !
Fingers crossed Lindy and the team have got the science right!
Take care all ..
Sign In
Follow the stocks
